Ornithine decarboxylase levels in peripheral nerve sheath tumors from NF1 patients

Clicks: 2
ID: 324795
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #8 of 103 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract OBJECTIVE The study was conducted to determine the level of ornithine decarboxylase (ODC) activity in several types of peripheral nerve sheath tumors to assess ODC as a potential target for alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC. METHODS A formalin-fixed paraffin-embedded peripheral nerve sheath tumor tissue microarray was developed in the Department of Anatomic Pathology, MD Anderson Cancer Center. ODC levels were measured using immunofluorescence with a polyclonal antibody to ODC and Alexa-Fluor 647 goat anti-rabbit IgG using previously validated and established methodology. RESULTS Nuclear and cytoplasmic ODC levels were assessed to determine surrogate ODC activity based on immunofluorescence from eleven patients with a spectrum of nerve sheath tumors, including malignant peripheral nerve sheath tumors (MPNSTs), plexiform neurofibroma, WHO Grade 1 (NF), atypical neurofibroma neoplasm of uncertain biologic potential (atypical ANNUBP), and schwannoma. ODC activity was less than 5 nmol/30 min/min/ug ODC protein in many MPNST, NF, and schwannomas, but higher than 10 nmol/min/ug protein in ANNUBP tumors and one NF tumor. CONCLUSION Nuclear ODC activity varied across peripheral nerve sheath tumors, with relatively low to moderate levels observed in MPNSTs and higher levels in atypical ANNUBP tumors within the small cohort studied. Since DFMO, an irreversible ODC inhibitor, is more effective in slow-growing grade 2 and 3 gliomas with low ODC levels than in higher malignancy grade 4 glioma with high ODC activity1, it is reasonable to assume that MPNSTs and neurofibromas, WHO grade, with relatively low to moderate levels of ODC activity may be suitable candidates for DFMO therapy. However, larger studies are needed to validate ODC activity as a predictive biomarker and to determine the therapeutic efficacy of DFMO in peripheral nerve sheath tumors.
Reference Key
openalex_W7202243228 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Victor A. Levin, Sonali Panchabhai, Rasha Alfattal, Gregory N. Fuller
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag208
URL
https://doi.org/10.1093/noajnl/vdag208
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.